Tokyo Tape
Sign in
← Taiko Pharmaceutical

Quarterly report · Q3

4574.TEDINET S100PJWU
Period2022-01-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥3.4bn2022-01-01 → 2022-09-30Cons.Net sales
Revenue¥11.3bn2021-01-01 → 2021-12-31Cons.Net sales (5-year summary)
Revenue¥8.4bn2021-01-01 → 2021-09-30Cons.Net sales
Operating income−¥2.8bn2022-01-01 → 2022-09-30Cons.Operating income
Operating income−¥1.6bn2021-01-01 → 2021-09-30Cons.Operating income
Ordinary income−¥2.9bn2022-01-01 → 2022-09-30Cons.Ordinary income
Ordinary income−¥6.1bn2021-01-01 → 2021-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥2.4bn2021-01-01 → 2021-09-30Cons.Ordinary income
Profit before tax−¥3.2bn2022-01-01 → 2022-09-30Cons.Income before income taxes
Profit before tax−¥2.6bn2021-01-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)−¥3.2bn2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥9.6bn2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥1.9bn2021-01-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income−¥3.2bn2022-01-01 → 2022-09-30Cons.Profit loss
Net income−¥1.9bn2021-01-01 → 2021-09-30Cons.Profit loss
Total assets¥16.5bnat 2022-09-30Cons.Assets
Total assets¥22.5bnat 2021-12-31Cons.Assets
Total assets¥28.5bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥6.7bnat 2022-09-30Cons.Liabilities
Total liabilities¥9.7bnat 2021-12-31Cons.Liabilities
Net assets / equity¥9.8bnat 2022-09-30Cons.Net assets
Net assets / equity¥12.8bnat 2021-12-31Cons.Net assets
Net assets / equity¥20.4bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥3.4bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥5.8bnat 2021-12-31Cons.Cash and deposits
EPS (basic)¥-72.972022-01-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-8.82022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-220.522021-01-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-44.792021-01-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥9.752021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio59.6%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio56.8%at 2021-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio71.6%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-09-30−¥893m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥976m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥976m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentsegment profit2022-01-01 → 2022-09-30−¥1.8bn
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue2022-01-01 → 2022-09-30¥5m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue external2022-01-01 → 2022-09-30¥5m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentsegment profit2022-01-01 → 2022-09-30−¥14m
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥2.4bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥2.4bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-09-30−¥42m
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-09-30¥3.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-09-30¥3.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-09-30−¥1.9bn
Reconciling Itemsreconcilingsegment profit2021-01-01 → 2021-09-30−¥1.1bn
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue2021-01-01 → 2021-09-30¥5.3bn
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue external2021-01-01 → 2021-09-30¥5.3bn
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentsegment profit2021-01-01 → 2021-09-30−¥1.5bn
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue2021-01-01 → 2021-09-30¥5m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue external2021-01-01 → 2021-09-30¥5m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentsegment profit2021-01-01 → 2021-09-30−¥21m
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2021-01-01 → 2021-09-30¥3.0bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2021-01-01 → 2021-09-30¥3.0bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2021-01-01 → 2021-09-30¥1.0bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-01-01 → 2021-09-30¥8.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-01-01 → 2021-09-30¥8.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-01-01 → 2021-09-30−¥506m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 372
ItemContextValueUnit
Total number of shares held treasury shares etcCurrentQuarterInstant_Row1Member499800
Shareholding ratio treasury shares etcCurrentQuarterInstant_Row1Member0.0113
Number of shares held in own name treasury shares etcCurrentQuarterInstant499800
Number of shares held in others names treasury shares etcCurrentQuarterInstant－
Total number of shares held treasury shares etcCurrentQuarterInstant499800
Shareholding ratio treasury shares etcCurrentQuarterInstant0.0113
Number of male directors and other officersFilingDateInstant5
Number of female directors and other officersFilingDateInstant－
Ratio of female directors and other officersFilingDateInstant－
Cash and depositsPrior1YearInstant5796000000JPY
Cash and depositsCurrentQuarterInstant3403000000JPY
Notes and accounts receivable tradePrior1YearInstant4056000000JPY
Notes and accounts receivable tradeCurrentQuarterInstant1849000000JPY
Short term investment securitiesPrior1YearInstant302000000JPY
Short term investment securitiesCurrentQuarterInstant701000000JPY
Merchandise and finished goodsPrior1YearInstant2010000000JPY
Merchandise and finished goodsCurrentQuarterInstant1032000000JPY
Work in processPrior1YearInstant536000000JPY
Work in processCurrentQuarterInstant604000000JPY
Raw materials and suppliesPrior1YearInstant659000000JPY
Raw materials and suppliesCurrentQuarterInstant708000000JPY
Other caPrior1YearInstant422000000JPY
Other caCurrentQuarterInstant356000000JPY
Current assetsPrior1YearInstant13783000000JPY
Current assetsCurrentQuarterInstant8656000000JPY
Buildings and structures netPrior1YearInstant2457000000JPY
Buildings and structures netCurrentQuarterInstant2301000000JPY
Machinery equipment and vehicles netPrior1YearInstant2378000000JPY
Machinery equipment and vehicles netCurrentQuarterInstant2123000000JPY
LandPrior1YearInstant1810000000JPY
LandCurrentQuarterInstant1807000000JPY
Construction in progressPrior1YearInstant72000000JPY
Construction in progressCurrentQuarterInstant2000000JPY
Other net ppePrior1YearInstant394000000JPY
Other net ppeCurrentQuarterInstant354000000JPY
Property plant and equipmentPrior1YearInstant7113000000JPY
Property plant and equipmentCurrentQuarterInstant6590000000JPY
Intangible assetsPrior1YearInstant299000000JPY
Intangible assetsCurrentQuarterInstant244000000JPY
Investment securitiesPrior1YearInstant1011000000JPY
Investment securitiesCurrentQuarterInstant616000000JPY
Other ioaPrior1YearInstant327000000JPY
Other ioaCurrentQuarterInstant366000000JPY
Investments and other assetsPrior1YearInstant1338000000JPY
Investments and other assetsCurrentQuarterInstant983000000JPY
Noncurrent assetsPrior1YearInstant8751000000JPY
Noncurrent assetsCurrentQuarterInstant7818000000JPY
AssetsPrior1YearInstant22535000000JPY
AssetsCurrentQuarterInstant16474000000JPY
Notes and accounts payable tradePrior1YearInstant309000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2021-12-31pass
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2021-12-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-01-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass